Beam therapeutics inc
BEAM 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
BEAM 近期報酬表現
-5.01%
Beam therapeutics inc
0.54%
同產業平均
-0.46%
S&P500
與 BEAM 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
NTLA | Intellia therapeutics inc | 5 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
EDIT | Editas medicine inc | 2 分 | 1 分 | 2 分 | 1 分 | 1 分 | |
CRSP | Crispr therapeutics ag | 2 分 | 1 分 | 1 分 | 3 分 | 1 分 | |
VERV | Verve therapeutics inc | - | 1 分 | 1 分 | 3 分 | 1 分 | |
DNLI | Denali therapeutics inc | 4 分 | 1 分 | 2 分 | 3 分 | 1 分 |
- NTLA Intellia therapeutics inc價值 5 分趨勢 1 分波段 2 分籌碼 3 分股利 1 分查看更多
BEAM 公司資訊
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.